|
ARID2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.44629999993585E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.33720000000815E-05 |
| Normal-vs-Stage2 |
4.080600E-03 |
| Normal-vs-Stage3 |
6.60660000040281E-08 |
| Normal-vs-Stage4 |
1.27349999989868E-07 |
| Stage1-vs-Stage2 |
8.232600E-01 |
| Stage1-vs-Stage3 |
2.671900E-02 |
| Stage1-vs-Stage4 |
1.428160E-02 |
| Stage2-vs-Stage3 |
7.432500E-02 |
| Stage2-vs-Stage4 |
2.734300E-02 |
| Stage3-vs-Stage4 |
4.289000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.35540000001377E-06 |
| Normal-vs-AfricanAmerican |
1.725700E-02 |
| Normal-vs-Asian |
1.991170E-04 |
| Caucasian-vs-AfricanAmerican |
5.838000E-01 |
| Caucasian-vs-Asian |
9.736600E-01 |
| AfricanAmerican-vs-Asian |
6.013200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.56488999999427E-05 |
| Normal-vs-Female |
1.84930000002304E-06 |
| Male-vs-Female |
8.286400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.93019999999678E-05 |
| Normal-vs-Age(41-60Yrs) |
2.1610999999977E-05 |
| Normal-vs-Age(61-80Yrs) |
3.54460000018264E-07 |
| Normal-vs-Age(81-100Yrs) |
2.524100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.580000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.922500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.658960E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.861600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.339400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.235400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.808000E-04 |
| Classical-VS-Follicular |
8.670000E-01 |
| Classical-VS-Other |
9.375800E-01 |
| Classical-VS-Normal |
3.95520000000538E-05 |
| Tall-VS-Follicular |
6.398700E-03 |
| Tall-VS-Other |
1.305560E-01 |
| Tall-VS-Normal |
5.08599999893278E-08 |
| Follicular-VS-Other |
9.844200E-01 |
| Follicular-VS-Normal |
6.550800E-04 |
| Other-VS-Normal |
1.019360E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.34469999999187E-06 |
| Normal-vs-N1 |
4.68180000001706E-06 |
| N0-vs-N1 |
3.775400E-01 |
|
|
